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Abstract
Many regulations are beginning to explicitly require investigation of a chemical's endocrine‐disrupting properties as a part
of the safety assessment process for substances already on or about to be placed on the market. Different jurisdictions are
applying distinct approaches. However, all share a common theme requiring testing for endocrine activity and adverse
effects, typically involving in vitro and in vivo assays on selected endocrine pathways. For ecotoxicological evaluation, in vivo
assays can be performed across various animal species, including mammals, amphibians, and fish. Results indicating activity
(i.e., that a test substance may interact with the endocrine system) from in vivo screens usually trigger further higher‐tier in
vivo assays. Higher‐tier assays provide data on adverse effects on relevant endpoints over more extensive parts of the
organism's life cycle. Both in vivo screening and higher‐tier assays are animal‐ and resource‐intensive and can be technically
challenging to conduct. Testing large numbers of chemicals will inevitably result in the use of large numbers of animals,
contradicting stipulations set out within many regulatory frameworks that animal studies be conducted as a last resort.
Improved strategies are urgently required. In February 2020, the UK's National Centre for the 3Rs and the Health and
Environmental Sciences Institute hosted a workshop (“Investigating Endocrine Disrupting Properties in Fish and Amphibians:
Opportunities to Apply the 3Rs”). Over 50 delegates attended from North America and Europe, across academia, labo-
ratories, and consultancies, regulatory agencies, and industry. Challenges and opportunities in applying refinement and
reduction approaches within the current animal test guidelines were discussed, and utilization of replacement and/or new
approach methodologies, including in silico, in vitro, and embryo models, was explored. Efforts and activities needed to
enable application of 3Rs approaches in practice were also identified. This article provides an overview of the workshop
discussions and sets priority areas for follow‐up. Integr Environ Assess Manag 2021;00:1–17. © 2021 The Authors. Integrated
Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental
Toxicology & Chemistry (SETAC).
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BACKGROUND
An endocrine‐disrupting chemical (EDC) is defined as “an
exogenous substance or mixture that alters function(s) of the
endocrine system and consequently causes adverse health
effects in an intact organism, or its progeny, or (sub)pop-
ulations” (WHO/IPCS, 2002). There are concerns regarding
the potential for chemicals to cause endocrine disruption
(ED) in humans and wildlife populations. Multiple regional
chemical regulations now explicitly require that ED proper-
ties be investigated as part of the approval process. Testing
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requirements currently range from mandated testing for all
substances, exposure‐based prioritization programs, and
concern‐triggered testing. The approaches implemented
vary by jurisdiction; however, all share common themes of
testing for endocrine activity and/or adverse effects (cf.
ECHA/EFSA, 2018; Japan Ministry of the Environment,
2010; USEPA, 2020).
Testing for endocrine activity (i.e., alteration of the en-
docrine system potentially leading to adverse effects) usu-
ally involves specific in vitro or in vivo assays evaluating
selected endocrine pathways. For ecotoxicological pur-
poses, there are several different validated in vivo guide-
lines that utilize mammals, amphibians, or fish. Results
indicating activity in initial tests often trigger further in vivo
assays that require larger numbers of animals. These assays
provide data on adverse effects and endocrine‐relevant
endpoints over more extensive parts of the organism's
life cycle. Such “higher‐tier” assays are animal‐ and resource‐
intensive and technically challenging to conduct. Such
studies also need to distinguish endocrine‐specific re-
sponses from those that might be a secondary consequence
from systemic or general toxicity; often, this is very difficult
to elucidate in the absence of whole animal experiments.
The need to assess chemicals for endocrine activity coupled
with the reliance on in vivo screening and higher‐tier
assays is driving the use of large numbers of animals. For
example, a recent study (Lagadic et al., 2019) estimated
that the plant protection product (PPP) and biocidal product
active substances currently registered in the EU would re-
quire >190 000 and >1 200 000 fish and amphibians for
mechanistic and adversity testing, respectively. This
animal use contradicts growing mandates globally, which
increasingly demand that safety assessment move to an
“animal‐free” paradigm (e.g., Burden et al., 2015; USEPA,
2019). This highlights the need to further consider how the
3Rs—the replacement, refinement, and reduction of the use
of animals (Russell & Burch, 1959)—can be applied.
PURPOSE AND OBJECTIVES
In February 2020, the UK's NC3Rs and HESI (see Sup-
porting Information S1 for more details) collaboratively
brought together experts in the field of ED to participate in
a workshop centered around the elucidation of estrogenic/
androgenic/thyroid/steroidogenesis (EATS) modalities in
fish and amphibians. Delegates were selected by the bal-
anced (authorities, academia, industry, HESI, and NC3Rs)
organizing committee based on technical expertise, sector,
and geographic spread (predominantly Europe and North
America). Delegates shared their knowledge and experi-
ences in (a) planning, conducting, and evaluating in vivo
studies and (b) developing and applying nonanimal and/or
replacement approaches, also known as new approach
methodologies (NAMs), for the assessment and identi-
fication of environmental ED. The workshop was attended
by 51 scientists from Europe and North America, primarily
from government and regulatory agencies (33%);
the (agro)chemicals, consumer products, biocides, and
pharmaceutical industries (25%); contract research organ-
izations (CROs; 16%); and academia (14%). The remainder
(12%) were consultants or represented learned societies.
Expertise areas covered aquatic ecotoxicology, mamma-
lian toxicology, in silico, in vitro, and modeling sciences.
The key objectives were as follows:
▪ Identify the 3Rs challenges and opportunities;
▪ Explore how replacement approaches and/or NAMs (e.g.,
in vitro, in silico, and early life‐stage embryos) or refined
and/or reduction approaches could potentially be used in
decision‐making;
▪ Share experiences across sectors and disciplines to iden-
tify collaboration opportunities that maximize the impact
of 3Rs approaches; and
▪ Identify knowledge gaps that, if addressed, could have a
significant impact on the application and acceptance of
3Rs approaches.
Discussions focused on identifying the next steps needed
to progress and increase confidence in the use of replace-
ment and refined and/or reduction approaches for EDC
identification with the understanding that regulatory agen-
cies may have a need to make decisions based on the cur-
rent state of the science. The discussion areas covered (1)
the current state of the science regarding animal testing, (2)
the current state of the science regarding which NAM and/or
replacement approaches are available or possible (covering
in silico, in vitro, and nonprotected embryo methods (EFSA,
2005; European Commission, 2010), and (3) applying 3Rs
approaches in practice. This manuscript, written by the
workshop organizing committee in conjunction with a
small number of delegates, provides an overview of those
discussions, as well as information gathered from delegates
prior to the workshop, and the resulting recommendations.
This manuscript is not intended as a consensus statement
agreed to by all the workshop participants. It represents
a summary, prepared primarily by the organizing com-
mittee, which we believe to be a balanced reflection of
the discussions and a valuable resource to guide progress in
the field.
CURRENT TESTING REQUIREMENTS AND THE
NEED FOR PROBLEM FORMULATION
There are variations in approaches to ED identification
and assessment dependent on the intended chemical use
and where the product is marketed. Currently, the most
regulatory advanced strategies exist for PPPs and biocidal
product active substances, including the European Chem-
icals Agency (ECHA)/European Food Safety Authority (EFSA)
guidance for the identification of endocrine disruptors
and the US Environmental Protection Agency (USEPA)
Endocrine Disruptor Screening Program (EDSP; see Table 1)
(ECHA/EFSA, 2018; USEPA, 2020). In addition, some non‐
pesticidal chemicals that meet potential exposure route re-
quirements are also subject to EDSP testing. This is largely
due to potential for environmental exposure and intended
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TABLE 1 Overview of major geographical testing requirements using fish or amphibians for ED identification and assessment
across industry sectors
Region Substance type Legal basis
Requirements for endocrine testing
using fish or amphibian models
Europe Plant protection products Commission regulation (EU) 2018/605
amending Annex II to Regulation (EC)
No. 1107/2009 by setting out scientific
criteria for the determination of
endocrine‐disrupting properties
OECD CF (OECD, 2018b) toolbox
adopted.
The ED assessment comprises two tiers
(ECHA/EFSA, 2018):a
(1) an assessment of the mammalian
data set.
(2) if it cannot be concluded based on
point 1 that the substance has ED
properties, then the generation of
new information on fish and
amphibians shall be considered.
Biocidal products Commission Delegated Regulation (EU)
2017/2100 setting out scientific criteria
for the determination of endocrine‐
disrupting properties pursuant to
Regulation (EU) No. 528/2012
Specific studies in fish may include a
MEOGRT (OECD TG 240) or a fish life
cycle study covering all the “estrogen,
androgen, or steroidogenesis‐
mediated” parameters foreseen to be
measured in OECD TG 240. Specific
studies in amphibians may include a
LAGDA (OECD TG 241).
These studies do not need to be
performed if endocrine activity is
sufficiently investigated (i.e., a test
according to OECD TG 229/230 and
OECD TG 231 is available) and there is
no indication that the substance has
endocrine activity or effects potentially
related to endocrine activity.
Industrial chemicals Regulation (EC) No. 1907/2006
concerning REACH
EDs identified as SVHC or equivalent
level of concern (see Article 57(f)) are
included in the candidate list and are
subject to authorization and/or
restriction processes. During 2021, the
CARACAL subgroup will discuss
revision of information requirements to
specifically address ED.
Human pharmaceuticals Regulation (EC) No. 726/2004 Currently, the European Medicines
Agency's Committee for Medicinal
Products for Human Use (CHMP)
guideline (CHMP 2006) specifies that
environmental risks of certain
compounds, including endocrine
active, need to be addressed
irrespective of exposure. Some
outlined guidance on testing
approaches is also available in the
accompanying Q&A document
(CHMP 2010).
A draft revision of the guidance by the
CHMP released in 2018 (CHMP 2018)
retains the requirements for tailored
risk assessment for endocrine‐active
substances and makes more specific
recommendations for the mechanism
of action‐specific testing, including the
following:
(Continued )
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TABLE 1 (Continued )
Region Substance type Legal basis
Requirements for endocrine testing
using fish or amphibian models
• OECD TG 229 fish short‐term
reproduction assay.
• OECD TG 230 21‐day fish screening
assay.
• OECD TG 234 fish sexual
development test.
• OECD TG 240 medaka extended
one‐generation test.
• OECD TG 241 larval amphibian
growth and development assay.
Veterinary pharmaceuticals Regulation (EC) No. 2001/82/EC Required studies (VICH 2000; VICH
2004)b do not currently include studies
specifically designed to identify
endocrine‐mediated effects.
Information from mechanism of action,
mammalian toxicology, or open
literature studies can inform requests
for additional studies.
USA Pesticides, pesticidal formulation
inert chemicals, and
environmental contaminants
found in drinking water to which
a substantial population is
exposed
EDSP 1998 Federal Register Notices EDSP uses a two‐tiered approach:a
Tier I
• 11 August 1998: Endocrine
Disruptor Screening Program










52 pesticides on List 1 have been
subjected to Tier I screening and no
test orders for Tier II testing have been
issued as yet. List 1 includes chemicals
that the EPA selected based on
exposure potential.
The EPA is currently focusing on the
pivot strategy of developing and
implementing NAMs as alternatives.
Over time, the goal is to develop a set
of “non‐animal” high‐throughput assays
and computational bioactivity models
as alternatives for all the assays in the
current Tier 1 screening battery.
Human pharmaceuticals US: National Environmental Policy Act of
1969 Code of Federal Regulations (CFR)
Part 25—ENVIRONMENTAL IMPACT
CONSIDERATIONS
The US Federal Drug Administration
(FDA) has issued both a general
guidance for ERA (FDA 1998) and a
Q&A for endocrine active substances
(FDA 2016). Neither of these request
specific studies, but applicants are
encouraged to requested to consult
the Agency prior to submission.
Japan Chemical substances Japan Chemical Substance Control
Law (2011)
The Japanese strategy uses a two‐tiered
approach:a
Current strategic program EXTEND
2010
Tier I
• Medaka estrogen receptor a reporter
gene assay.
(Continued )
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biological activity, making potential adverse effects to
nontarget organisms a concern. Other substance types,
such as human and veterinary pharmaceuticals and in-
dustrial chemicals, will have less direct exposure pathways
into the environment (e.g., via wastewater). By their nature,
pharmaceuticals also have intended biological activity—
some specifically with intended endocrine properties in
vertebrates (as do some pesticides that target insect en-
docrine systems). The identification of the potential for
endocrine‐mediated effects of pharmaceuticals and in-
dustrial chemicals currently tends to rely on (1) the follow‐up
of flags identified by their intended mode of action (MoA),
(2) findings (e.g., reproductive effects) within standard
chronic testing (particularly in mammals), (3) potential issues
identified by read‐across and/or identification of structural
similarities, or (4) information from open literature studies.
The geographical differences in approach are also marked
in some sectors, noting the risk‐based approach adopted in
North America and Japan compared with the hazard‐based
approach often favored in Europe. The European hazard‐
based approach effectively prevents consideration of ex-
posure in the assessment; although there is a legislative
allowance for use under “negligible exposure” conditions,
however, for the environment, this has not been defined.
Under this approach, a substance shown to be an EDC will
not be approved, resulting in it being removed from the
market or its use severely restricted, regardless of whether
safe uses can be identified.
The data needs and testing requirements for EDC
identification and assessment are context dependent, and
it is critical that this context is identified and considered
upfront via a problem formulation process. The problem
formulation step of any human health or environmental
safety assessment seeks to define the scope of the as-
sessment to best determine the data, tools, and proce-
dures required to complete the evaluation. This ensures
that the assessment is “fit for purpose” and meets the
overall (risk) management goal (Solomon et al., 2016) so
that the data generated add value to the decision‐making
process and support the selection of studies, in line with
the 3Rs. It should be noted that although there are varia-
tions in geographical approach, ultimately, many products
are intended for wide geographical or global use. Testing
requirements or test packages will therefore usually be
designed to ensure that all the likely relevant global
requirements are fulfilled.
In 2012, the Organization for Economic Cooperation and
Development (OECD) published Guidance Document (GD)
150 on Standardised Test Guidelines for Evaluating Chem-
icals for Endocrine Disruption; this framework provides a
guide to the tests available, rather than setting out a testing
strategy (OECD, 2012). GD 150 was updated in 2018 to
reflect the newer and revised OECD test guidelines (TGs)
and to capture scientific advances in the use of test methods
and assessment of the endocrine activity and endocrine‐
mediated effects of chemicals (OECD, 2018b). The OECD
conceptual framework (CF) (OECD, 2012) describes the
available (validated and those anticipated to be validated)
assays across five “levels”: (1) existing data and/or nontest
information, (2) in vitro assays providing data about selected
endocrine mechanism(s) or pathway(s), (3) in vivo assays
providing data about selected endocrine mechanism(s) or
pathway(s), (4) in vivo assays providing data on adverse ef-
fects on endocrine‐relevant endpoints, and (5) in vivo assays
providing more comprehensive data on adverse effects on
endocrine‐relevant endpoints over more extensive parts of
the organism's life cycle. The framework is not a testing
strategy, but is a toolbox that can be entered and exited at
any level depending on information needs and the regu-
latory framework in which an evaluation is performed. OECD
GD 150 (OECD, 2018b) has largely been used as a basis to
inform the development of endocrine‐specific data re-
quirements or GDs (such as those highlighted in Table 1) for
the implementation of the scientific criteria. Some of these
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TABLE 1 (Continued )
Region Substance type Legal basis
Requirements for endocrine testing
using fish or amphibian models
• Medaka androgen receptor b
reporter gene assay.
• AMA (OECD TG 231).
• Fish screen (i.e., OECD TG 229
or 230).
• JMASA (under development).
Tier II
• LAGDA (OECD TG 241)
• MEOGRT (OECD TG 240)
Abbreviations: AMA, Amphibian Metamorphosis Assay; CARACAL, Competent Authorities for REACH and CLP; CF, conceptual framework; ED, endocrine
disruption/disruptor; EDSP, Endocrine Disruptor Screening Program; EXTEND, Extended Tasks on Endocrine Disruption; JMASA, Juvenile Medaka Anti‐
androgen Screening Assay; LAGDA, Larval Amphibian Growth and Development Assay; MEOGRT, Medaka Extended One‐Generation Reproduction Test;
NAM, new approach methodology; OECD, Organization for Economic Cooperation and Development; SVHC, substance of very high concern; TG, test
guideline; USEPA, US Environmental Protection Agency.
aOther in vitro and mammalian‐based assays are also required (OECD or USEPA equivalent TGs normally also accepted).
bAlso applies to the USA and Japan.
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came into force recently (e.g., for PPPs in the European
Union [ECHA/EFSA, 2018]) or are anticipated in the near
future (e.g., amendments to the European Union's Regis-
tration, Evaluation, Authorisation and Restriction of Chem-
icals [REACH] regulation annexes; updates to the European
Medicines Agency [EMA] guideline on the environmental
risk assessment of medicinal products for human use). Not
only are there variations in the specific tests required under
the different chemical regulations, but there are also dif-
ferences both in how weight‐of‐evidence (WoE) consid-
erations are applied, where a combination of evidence from
several sources is considered, and in how open literature is
used (Suter et al., 2020).
The existing and forthcoming requirements across all
chemical sectors will have a major impact on the number of
animals used in the identification and assessment of envi-
ronmental endocrine‐mediated effects. This is not only due
to the need for additional endocrine‐specific in vivo tests
but also because the tests can be complex and highly an-
imal intensive, particularly at the higher CF levels (see
Figure 1) (Lagadic et al., 2020).
POTENTIAL CHALLENGES WITH IDENTIFICATION
OF EDCS IN A REGULATORY CONTEXT
Throughout the three workshop discussion sessions, sev-
eral themes emerged reflecting the current challenges
facing EDC identification across all chemical sectors; how-
ever, it is acknowledged that not every one of these
challenges is applicable to all regulatory EDC identification
frameworks. These themes are as follows:
▪ A lack of high‐quality data, or data gaps, for identifying
ED, especially where specific tests are not a formal re-
quirement and where there is, by necessity, a stronger
reliance on the use of open literature.
▪ The difficulty in establishing the relevance of endocrine
effects observed in laboratory studies to the maintenance
of wild populations, which is the ultimate protection goal.
Currently, there is an assumption that all effects on
survival, growth, development, and reproduction will be
population‐relevant and the onus is to demonstrate non-
relevance of effects (ECHA/EFSA, 2018). This can lead to
some uncertainty as to how assessments might be refined
through additional data generation. Endocrine disruption‐
relevant adverse outcome pathways (AOPs) are currently
limited and are focused more on the first half of the AOP
(molecular initiating event [MIE], i.e., endocrine activity,
and MoA) than the second half (the apical adverse out-
come leading to impacts on populations). This is partly
related to challenges in linking the MIE with the apical
outcome in a scientific, quantitative, and rigorous way
(Lagadic et al., 2020).
▪ The complexity of data interpretation, including how to:
(a) deal with activity and/or effects within the historical
control range (e.g., as recommended in the Animal
Research: Reporting of In Vivo Experiments [ARRIVE]
guidelines) (Kilkenny et al., 2010);
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FIGURE 1 Overview of OECD TGs and standardized test methods available, under development, or proposed that can be used to evaluate chemicals for
activity and/or disruption, updated based on the OECD CF for Testing and Assessment of Endocrine Disrupters (OECD, 2012), including an overview of the
modalities that each assay is intended to identify (individual regulatory policies may differ on specifics), the TG validation status, and an indication of the
number of animals used per test. The CF is intended to provide a guide to the tests available that can provide information for ED assessment, but it is not
intended to be a testing strategy. Further information on the use and interpretation of these tests is available in OECD GD 150. Not all the tests are necessarily
requested, but OECD CF Level 3 positives may be a trigger for Level 4/5 studies. Note that, under the current EDSP, LAGDA data are considered primarily to
identify interactions with only the HPT axis. AFSS, androgenized female stickleback screen (OECD GD 148; variant of OECD TG 230); AMA, Amphibian
Metamorphosis Assay (OECD TG 231/OPPTS 890.1100); EDSP, Endocrine Disruptor Screening Program; FSA, Fish Screening Assay (OECD TG 230); FSDT, Fish
Sexual Development Test (OECD TG 234); FSTRA, Fish Short‐Term Reproduction Assay (OECD TG 229/OPPTS 890.1350); GD, guidance document; JMASA,
Juvenile Medaka Anti‐androgen Screening Assay; LAGDA, Larval Amphibian Growth and Development Assay (OECD TG 241/OCSPP 890.2300); MEOGRT,
Medaka Extended One‐Generation Reproduction Test (OECD TG 240/OCSPP 890.2200); OECD, Organization for Economic Cooperation and Development;
TG, test guideline; ZEOGRT, Zebrafish Extended One‐Generation Reproduction Test
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(b) deal with conflicting data, which can be dependent
on the study design and the species used;
(c) increase confidence in negative results from lower‐
tier in vitro studies;
(d) assign weight to individual results; and
(e) determine which results are indicative that in vivo
testing (for activity and/or adversity) is necessary.
▪ How to distinguish between a primary ED MoA from a
secondary MoA when in vivo effects are seen (i.e., when
are they endocrine‐mediated vs. caused by systemic
toxicity?) (Marty et al., 2018). The main challenge here
relates to the setting of the maximum tolerated concen-
tration (MTC) (Hutchinson et al., 2009; Wheeler et al.,
2013), which is mainly based on expert judgment. Further,
it can be challenging to perform an MoA analysis and
establish which modality underlies an impacted param-
eter, especially within studies in which several pathways
are investigated in parallel, an aspect not unique to
nonmammalian endocrine studies. This is not an issue
under risk‐based programs, where regulation is based on
the point of departure established, regardless of whether
an ED effect is the primary or secondary toxicity.
▪ The limited understanding of the specific contribution of
chemical exposure and the ability to distinguish ED ef-
fects from other possible causes (e.g., genetics and en-
vironmental factors). This highlights the need for
increased relevance of testing strategies.
▪ The gaps within current paradigms to identify effects in
nontarget organisms other than fish, amphibians, and wild
mammals (e.g., birds and reptiles) or to identify modalities
other than EATS.
The following sections discuss the challenges and 3Rs
opportunities identified related to the use of (a) in vivo TGs,
(b) the application of NAMs, and (c) applying the oppor-
tunities in practice.
Challenges and 3Rs opportunities in in vivo testing
In vivo testing challenges. The aim of this discussion session
was to deduce where the reduction and refinement oppor-
tunities lie, while understanding that, at present, regulatory
decisions require data generated from in vivo studies. As-
says using nonprotected embryos are considered in the next
section on NAMs. Table 1 summarizes the fish and am-
phibian studies currently required under some regional
regulatory programs where in vivo testing is mandated.
Figure 1 presents an overview of the modalities that each
assay is intended to identify, the TG validation status, and an
indication of the number of animals used in each assay. The
discussions identified both the advantages and the chal-
lenges posed using the currently available in vivo tools;
these are summarized in Table 2. Issues related to the use of
specific TGs were also raised, although in the interest of
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TABLE 2 Advantages and key challenges identified with generating
and using data from currently available in vivo TG assays
Advantages
▪ Meets needs to demonstrate adversity at the whole
organism level, as determined or required by the current
ED definition.
▪ Totality of the whole organism investigated, capturing
ADME and complex interactions (feedback and
compensatory); sensitive developmental stages may be
included.
▪ Increased confidence with increased evidence (i.e., multiple
studies in different species, life stages, and concentrations).
▪ For the EATS modalities, relatively broad coverage of TGs,
encompassing various known sensitive measures.
Key challenges
▪ Complexity: uses large numbers of animals, is expensive,
and lengthy timescales are needed to complete and
analyze studies.
o In addition to the main study, animal use to set up tests
can be extensive (e.g., compatibility screening for
reproductive groups; FSTRA and MEOGRT F0), and
there are issues with test concentration setting finding
(see below).
▪ Laboratory capacity and experience currently limited,
particularly for OECD CF Level 4/5 studies (cf. MEOGRT
and LAGDA) but also OECD CF Level 3 studies (cf. AMA
and FSTRA due to high demand in the EU).
o There is greater experience in conducting CF Level 3
studies (FSTRA and AMA), although no analysis has been
conducted as yet to identify potential for flexibility in
current performance criteria, leading to varying
regulatory acceptance of different outcomes. Due to
limited validation, experience gained with use should
inform any potential modifications to increase scientific
rigor. Even the OECD TGs indicate that this re‐evaluation
should be performed when there is more experience
using the test methods (e.g., of MEOGRT and LAGDA).
▪ High variability of key parameters measured (e.g.,
vitellogenin and reproduction).
▪ Multiple MoAs not differentiated in most studies.
o Adverse effects within the same study provide little
information on the actual mechanism; if effects are seen
in an OECD CF Level 3 study, a higher‐tier study using
more animals will usually be required.
▪ Awareness of test limitations needed, since study
designs may not be directly relevant to environmental
scenarios (i.e., some designed explicitly not to be),
particularly since there is divergence in scientific opinion
as to how important these issues are for robust regulatory
evaluations.
o They may not capture effects due to short exposure
duration, or sometimes, effects will be on a
multigenerational scale, very subtle, or occur at lower
exposures than those tested. Additionally, there are
questions around the relevance of individual test species
as surrogates for all environmental species.
▪ Measured endpoint(s) not necessarily representative
exclusively of endocrine‐specific effects (e.g., there is an
inability to differentiate between primary and secondary
endocrine MoA).
o Driven by a need for hazard identification, the highest
test concentrations feasible are promoted. This increases
the likelihood of observing secondary effects that could
(Continued )
3RS FOR INVESTIGATING ED PROPERTIES IN FISH AND AMPHIBIANS—Integr Environ Assess Manag 00, 2021 7
brevity, these will be discussed and addressed more thor-
oughly through future activities.
Reduction and refinement opportunities. Although largely
considered to be the “gold standard” and offering distinct
advantages, the challenges identified in Table 2 clearly
demonstrate that the currently available in vivo methods are
not perfect. There are several opportunity areas to build on
best practices, which could reduce the number of animals
used or increase the utility of information gained by im-
proving existing study design. It is critical to (a) consider
upfront whether fish and amphibian data are needed to
answer the regulatory question (acknowledging current
regulatory requirements); (b) ensure that the utility of the
data generated is maximized and adds value to the
assessment process; and (c) ensure that any additional
measurements incorporated into assays do not impact
the welfare of the test animals. The first aspect relates to
the need for problem formulation, and there is scope
to consider whether data from other study types and
species can provide the information on which to base a
regulatory decision. Many opportunities could be harnessed
through the exploitation of existing flexibility or the in-
troduction of greater flexibility within legal frameworks or
TGs (while noting that this could contribute to uncertainty
for registrants). This could include more options as to
which assays are used to meet specific information
requirements depending on the preexisting information.
In addition, it is recognized that there is some degree
of overlap between certain assays, and this redundancy
may be considered desirable. Most opportunity areas
identified relate to improving the data generated and its
interpretation:
(a) Improvements to concentration‐setting guidance and
subsequent data analysis or interpretation, which will
require an agreed‐upon definition on the MTC and de-
velopment of an optimized strategy. This will help to
separate out effects not specific to endocrine MoAs (e.
g., systemic toxicity) and thus increase confidence in the
results and maximize the information generated (fewer
confounded treatment levels).
(b) Review and update (if necessary) in vivo TGs to better
understand study performance and test validity criteria,
in terms of which criteria are fundamental to the per-
formance of the test and for which there are acceptable
levels of flexibility, particularly for higher‐level studies in
the OECD CF. There is currently no set mechanism (e.g.,
through the OECD) for review of established TGs and
assessment of their utility or relevance, although such a
review is recommended in both the OECD TGs for the
Medaka Extended One‐Generation Reproduction Test
(MEOGRT, OECD TG 240) and the Larval Amphibian
Growth and Development Assay (LAGDA, OECD TG
241). High‐quality historical control data can be used
to better understand the biological relevance of the
tests and facilitate understanding of variability within a
method; this will be critical when evaluating new ap-
proaches (e.g., NAMs) that may be alternatives to in vivo
TGs in the future. Note, variability within the methods
has at least two components: (1) intrinsic biological
variability and (2) controllable experimental variability
(organism source, husbandry, equipment, and per-
sonnel) (Brooks et al., 2019). A better understanding of
historical controls can also assist with interpretation is-
sues, ensuring the best use of in vivo test data (Wheeler
et al., 2019).
(c) Ensure that tests better address population relevance,
which may be key for their regulatory use, and that ap-
propriate extrapolations from laboratory to field can be
made. There would be utility in identifying appropriate
measures that support extrapolation to the population
level in a quantitative manner (e.g., through the devel-
opment and use of quantitative AOPs).
(d) Improving the application of WoE approaches, including
better utilization of existing data and greater consid-
eration of other vertebrate data, such as from mammals
(McArdle et al., 2020). Decisions to categorize a chem-
ical as an ED should not be made based on data from
one in vivo TG alone, and clear WoE guidance and ap-
proaches are needed. Under EDSP, the USEPA accepts
Other Scientifically Relevant Information (OSRI) sub-
missions in response to test orders; this may include
open literature and NAM data (USEPA, 2009). The wider
Integr Environ Assess Manag 2021:1–17 © 2021 The Authorswileyonlinelibrary.com/journal/ieam
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be mistaken for a direct interaction with the endocrine
system. This, coupled with a very low power to assess
clinical signs that might be indicative of systemic
challenge (e.g., body weight gain and/or body weight
loss‐type assessments, as measured in mammals), means
that false conclusions may be drawn.
▪ Lacking interpretative guidance.
o Sometimes, changes in single endpoints can be highly
diagnostic; in other instances, multiple, related
endpoints are needed to reliably assess pathway
perturbation (e.g., see Ankley & Jensen, 2014).
▪ Concentration level‐setting issues.
o Determining maximum tolerated concentrations is
problematic (life‐stage and species dependent);
extended range finding is often necessary; and there is
inconsistency between how this is recommended within
different OECD TGs.
▪ Potential for variation in sensitivity depending on species
choice (fathead minnow vs. medaka vs. zebrafish), which
can be driven by geographical preferences.
▪ Prescriptive nature of current data requirements (little room
for maneuver away from the default).
Abbreviations: ADME, absorption, distribution, metabolism, and excretion;
AMA, Amphibian Metamorphosis Assay; EATS, estrogenic/androgenic/
thyroid/steroidogenesis; CF, conceptual framework; ED, endocrine dis-
ruption/disruptor; FSTRA, Fish Short‐Term Reproduction Assay; LAGDA,
Larval Amphibian Growth and Development Assay; MEOGRT, Medaka
Extended One‐Generation Reproduction Test; MoA, mode of action;
OECD, Organization for Economic Cooperation and Development; TG,
test guideline.
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use of minimum reporting requirements, such as criteria
for reporting and evaluating ecotoxicity data (CRED)
(Moermond et al., 2016) and ARRIVE (Percie du Sert
et al., 2019), will aid in transparency and could help
facilitate better availability of data and their integration
into assessments. Mammalian‐based activity data
can also potentially better inform other vertebrate as-
sessments. However, the differences in the tox-
icokinetics (TK) of different exposure routes (e.g., oral
gavage or dietary with first‐pass metabolism in mammals
vs. aquatic exposure over the gill in fish) should be ad-
dressed as an uncertainty and highlights the need for a
better understanding of internal exposure differences
across species. The collation of case studies demon-
strating real‐life examples of how data from different
sources can and have been integrated to inform regu-
latory decision‐making would be beneficial.
(e) Adding value to existing tests through the addition of
endpoints (e.g., thyroid measurements in fish) and links
between activity and adversity within the same study
could reduce the number of different studies required.
However, it should be noted that this could further
confuse data interpretation and cause statistical issues if
too many endpoints are included in the same test. There
are also limitations on availability of plasma and tissue
samples for endpoint evaluation (e.g., a fish liver can be
used for vitellogenin mRNA or histopathology, but not
for both analyses).
(f) More emphasis on developing improved screening
tools to decrease the number of chemicals requiring
in vivo testing. There is a need to establish confidence
in lower‐tier in vitro negatives to avoid triggering
unnecessary higher‐tier studies, including gaining a
better understanding of false positives and false
negatives.
Challenges and 3Rs opportunities in NAMs
Challenges in NAMs. The aim of this discussion session was
to explore the current status of NAMs for regulatory decision‐
making and identify where the opportunities lie for replacing
(or reducing) in vivo TG studies. A range of approaches are
available, varying in speed of throughput and physiological
relevance, from computational and in silico models, in vitro
assays using immortalized cells or primary tissues or cells,
through to assays using nonprotected embryos. It should be
noted that in many regions, embryos, until they reach the free‐
feeding life stage, are not protected under animal welfare
legislation in the same way as juvenile and adult fish and
amphibians (European Commission, 2010). At this life stage,
embryos are considered in capable of experiencing pain,
distress, suffering, or lasting harm (EFSA, 2005) and are con-
sidered a NAM. For a list of NAM examples, see Table 3. For
now, NAMs are only used to provide supporting information
within data packages. However, NAM data are starting to be
considered within a regulatory context as follows:
▪ In vitro consensus approaches have been proposed by
the USEPA for estrogen receptor (ER) (USEPA, 2015) and
androgen receptor (AR) activity (USEPA, 2017) (so‐called
“ER/AR pathway models”).
▪ A proposed integrated approach to testing and assess-
ment (IATA) for the ER has been published (OECD, 2018a;
Webster et al., 2019).
▪ Canada's Ecological Risk Classification approach (ERC2)
under its Chemicals Management Plan utilizes WoE ap-
proaches that incorporate in silico flags.
▪ In November 2020, ECHA/EFSA issued a draft addendum
to the GD (ECHA/EFSA, 2018) detailing under which
conditions they will accept data from the embryonic
Xenopus Eleutheroembryo Thyroid Assay (XETA, OECD
TG 248) for PPP and biocide registrations.
▪ The output from the ToxCast ER bioactivity model is ac-
cepted under the EFSA/ECHA guidance (ECHA/EFSA,
2018) as a replacement for the uterotrophic bioassay in
rodents (OECD TG 440, CF level 3).
Clearly, the tools applied will vary depending on the sci-
entific or regulatory question being posed, in line with the
need to consider problem formulation upfront.
The discussions identified both the advantages and the
challenges posed using the currently available NAMs for
decision‐making: these are summarized specific to assay
type in Table 4. Some challenges were identified that are
relevant to all NAM types. Participants felt that, currently,
NAMs hold most promise for initial chemical screening and
prioritization, and there is limited confidence in their use as
predictive tools in risk or hazard assessment. This is partly
due to a general lack of representation of complex bio-
logical processes and systems within the assays (e.g., ab-
sorption, distribution, metabolism, and excretion [ADME]).
There is a general concern around the risk of false negatives
or false positives, and there is a reluctance to make deci-
sions solely based on results from NAMs (although it should
be noted that it is also unclear how predictive the in vivo
studies are in comparison to the NAMs.) Validation studies
are usually conducted using reference compounds, which
provide strong negative or positive outcomes. However,
most “real‐world chemicals” tested for regulatory purposes
will not provide such clear effects, and there is a need to
ensure that assays can detect effects across a spectrum of
potencies. In general, there are limited NAMs covering key
pathways, especially for the thyroid modality, and not all
known mechanisms within a pathway are necessarily
captured. Further, although it is widely recognized that
IATAs will be the way forward for the application of NAMs in
practice (through the combination of data from multiple
sources), the current OECD process for IATA adoption is
rigid, conservative, and lengthy (5–10 years). It typically re-
quires that data are generated using official TG methods,
which can take many years to validate, although
“performance‐based test guidelines” (PBTGs) are now
beginning to be considered; there may be faster ways to
enable adoption more broadly within regulatory agencies.
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Finally, the new approaches are also not necessarily
cost‐effective compared to established in vivo approaches,
and until there is a stronger regulatory need or mandate
for them, they will not be offered as routine services
by CROs.
Maximizing replacement opportunities. The NAM field for
ED assessment has come a long way in recent years (Scholz
et al., 2013), although there are still fundamental biology
questions that remain unanswered and there is a general
lack of confidence in the interpretation and use of NAM data
on a wider scale. This presents several opportunity areas to
either fill knowledge gaps or enhance integration and
applicability within current testing paradigms toward truly
tiered approaches:
(a) Expanding on the tools available and increasing cov-
erage of biological domains. It would be useful to “map”
the tools currently (or soon to be available) in the
molecular realm to identify knowledge gaps and inform
targeted assay development where needed. Such
mapping exercises should lay out the NAMs along en-
docrine pathways to demonstrate the aspects that they
address within an AOP (MIE, key events, etc.) and
highlight which aspects are currently lacking. This work
is currently underway via multisector teams led by HESI
Integr Environ Assess Manag 2021:1–17 © 2021 The Authorswileyonlinelibrary.com/journal/ieam




Consensus QSAR models for ER and AR activity ER: CERAPP project
AR: CoMPARA project
Cross‐species extrapolation models (SeqAPASS)
and Automated Approach for Assessing
Protein (Molecular Target) Similarity
SeqAPASS (LaLone et al., 2016)
ToxCast ER and AR pathway models Integrates the results of multiple in vitro assays
providing comprehensive coverage of the pathway
(Judson et al., 2015). In the EU, or human health
assessment, can be used in place of the uterotrophic
assay (ECHA/EFSA, 2018; USEPA, 2015). AR model
(Kleinstreuer et al., 2016) as for the ER model, but
less developed and not currently considered
equivalent to in vivo assays. In the US, considered for
determinations of “endocrine disruption screening.”
USEPA has proposed the ER pathway model as
an alternative to the ER in vitro assays and the
uterotrophic assay (USEPA, 2015), and the AR model
(Kleinstreuer et al., 2017) has been subjected to
extensive peer review.
In vitro assays ToxCast ToxCast contains 18 different high‐throughput assay
technologies measuring different points along the
ER signaling pathway (Judson et al., 2015), plus
AR‐related assays (Kleinstreuer et al., 2017), H295R
steroidogenesis (Karmaus et al., 2016), and multiple
thyroid assays.
Embryo assays XETA Published Test Guideline—OECD TG 248
REACTIV assay Approved as an OECD project in 2020
EASZY assay Draft OECD Test Guideline
RADAR assay Draft OECD Test Guideline
Transcriptomic
approaches
EcoToxChips qPCR arrays and data evaluation tool (EcoToxXplorer.
ca) for the characterization, prioritization, and
management of environmental chemicals and
complex mixtures of regulatory concern.
Transcriptomic dose–response modeling To establish whether the lowest dose to induce
significant transcriptomic changes corresponds to the
safe long‐term exposure dose.
Abbreviations: AR, androgen receptor; CERAPP, Collaborative Estrogen Receptor Activity Prediction Project; CoMPARA, Collaborative Modeling Project for
Androgen Receptor Activity; EASZY, Endocrine Active Substance, acting through estrogen receptors, using transgenic cyp19a1b‐GFP Zebrafish embrYos;
ECHA, European Chemicals Agency; EDC, endocrine‐disrupting chemical; EFSA, European Food Safety Authority; ER, estrogen receptor; NAM, new approach
methodology; OECD, Organization for Economic Cooperation and Development; qPCR, quantitative PCR; QSAR, quantitative structure–activity relationship;
RADAR, Rapid Androgen Disruption Adverse Outcome Reporter; REACTIV, Rapid Estrogen ACTivity In Vivo; TG, test guideline; XETA, Xenopus Eleuther-
oembryo Thyroid Assay.
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▪ Rapid and potentially cost‐saving screening
methods to prioritize testing of chemicals with
the potential to interact with the endocrine
system.
▪ Avoids use of highly expensive test materials
during early development of new chemicals.
▪ Can be based upon multiple data (in vivo, in
vitro, embryonic) on a breadth of to support
WoE and reduce reliance on individual assays.
▪ Can be used to prioritize testing (e.g., cross‐
species extrapolations can help identify testing
needs based on level of conservation of
receptors and proteins).
▪ Presently, QSARs can only predict activity and
not adverse effects and are not available for
more complex exposure and effect situations.
Receptor binding models are reliable, but do
not indicate the whole organism implications—
lack of relevance at the individual and/or
population level.
▪ Built based on existing data—the quality
of the model is dependent on the
quality of the available data. Error
from experimental tests is passed along to
the model.
▪ Currently parameterized on existing training
sets that can be limited in chemical domain
breadth compared to other (eco)toxicological
endpoints.
▪ Models limited in their design and focus on few
key events along the EATS axes.
▪ Currently limited models for thyroid and
steroidogenesis modalities.
▪ Use of high‐throughput techniques
requires harmonized bioinformatics pipelines
and tools.
In vitro and embryo
assays
▪ Small in scale, can be used for screening.
▪ Useful starting point if there is a suspected MoA
based on analogues particularly for defined
pathways with identified MIEs; allows for high‐
throughput screening using NAMs focused on
particular MIEs rather than investigating every
and all MoAs.
▪ Minimizes use of highly expensive test materials
during early development of new chemicals.
▪ Useful where in vivo effects have been
observed and data on MoA are required to
support a WoE.
▪ Quick results, can be cheaper (but not always).
▪ Significant potential to help understand cause
and effect at a cellular level and target in vivo
testing.
▪ In vitro methods do not generally include
metabolism, tissue interactions, or consider the
whole organism complexity/life cycle.
▪ IVIVE is needed to understand relevant
exposures.
▪ Short‐term studies and exposure duration may
not be sufficient to observe endocrine‐mediated
effects.
▪ Tests can be expensive, given the
resource required to validate results,
including analytical support. May need
multiple tests to cover one pathway (cf. the ER
model [Judson et al., 2015]). Can be difficult to
justify the cost, and decisions may be made
that money could be better spent on higher‐
tier, more definitive studies.
▪ Negative in vitro tests not currently sufficient to
demonstrate lack of endocrine activity in vivo in
some regions.
▪ Full suite of methods covering all MoAs not yet
available.
▪ Assays currently use predominantly mammalian
cell lines, which adds to uncertainty regarding
relevance to nonmammalian outcomes.
Specific to embryo
assays
▪ Captures the complexity of the whole organism,
which can include an element of metabolism,
and use of a potentially sensitive life stage.
Most biological processes are represented at
the molecular level (even if physiological
activity is not occurring yet).
▪ Can be directly calibrated with
apical outcomes from current in
vivo TGs and substances can be
assessed in the context of relevant endpoints,
such as behavior and developmental toxicity,
to help elucidate relevance of the endocrine
MoA.
▪ Native genes and/or endpoints available in fish
embryos for estrogens and thyroid
hormones only.
▪ Androgens accessible via artificial ARE
constructs or by cloning the spiggin (stickleback)
promotor.
▪ Transgenic models may be too narrow in scope,
requiring the use of multiple different models
and approaches. As for in vitro assays, can
therefore be difficult to justify the cost.
▪ Chorion impermeable to some compounds.
▪ Suite of OECD embryo TGs are expected in the
near future (but currently not available).
(Continued )
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and NC3Rs. The thyroid modality remains an area
where, despite the development of numerous NAM
assays for MIEs, there are no validated NAM TGs.
Transcriptomics data are becoming more available, al-
though better guidance is needed on how to use such
data and infer pathways and adverse effects; there is
also a need to compare points of departure in traditional
tests with transcriptomic points of departure on a wider
scale. Greater investment into sequencing and anno-
tating genomes would be beneficial and could support
efforts to extrapolate across species and increase un-
derstanding of differences in species or taxonomic
sensitivity (LaLone et al., 2016), which could then be
better captured within assays or in their interpretation.
Oviparous embryo models across multiple fish, am-
phibian, and bird species will be particularly attractive to
expand upon, as they are intact in vivo systems that
could help to address the limitations of current cell‐ or
tissue‐based in vitro tests. As well as covering more
species and increasing their use in test batteries, there is
a need to expand existing embryo protocols by in-
tegrating mechanistic toxicity information (e.g., through
gene fingerprinting to inform toxicity pathways or the
wider use of transgenic embryo assays, which are easier
to design now with technologies such as CRISPR [clus-
tered regularly interspaced short palindromic repeats]).
(b) Increasing confidence in the use of NAMs and data in-
terpretation. It is critical that training and education
around NAMs begin at the university level and engage
stakeholders across both research and policy making.
New tools should be discussed with regulatory agencies
at the earliest opportunity to ensure their utility and ul-
timate acceptance for decision‐making. This includes
clear demonstration of “proof of principle” and more
standardized ways of interpreting data, including a
harmonized WoE framework. There are currently many
different documents that cover aspects of WoE in use
across different agencies, including OECD GD 150
(OECD, 2018b), EFSA guidance on the use of the WoE
approach in scientific assessments (EFSA, 2017), USEPA
WoE guidance on interpreting results of the EDSP Tier I
battery of studies and identifying candidate chemicals
for additional testing with EDSP Tier II studies (USEPA,
2011), and a USEPA publication titled “Weight of
Evidence in Ecological Risk Assessment” (USEPA, 2016).
These documents support different regulatory contexts,
but combine essentially the same information in dif-
ferent ways. Machine learning and artificial intelligence
techniques as well as bioinformatics and sophisticated
statistical tools may be beneficial to deal with large data
sets and could also be useful in guiding method devel-
opment. A better understanding of nonspecific effects,
particularly for the thyroid modality, would be helpful, as
would development of a set of reference compounds to
benchmark all NAMs (acknowledging this would be
difficult to develop). Case studies that demonstrate the
value of different study types, including a combination
of formally validated and nonvalidated methods, would
be useful in the shorter term to build knowledge and
advance understanding, without waiting for the out-
comes of lengthy formal processes such as TG and IATA
development.
(c) Improving the application of systems toxicology ap-
proaches. Investigating ED is no different from examining
any type of MoA, and this lends itself to the application of
pathways‐based approaches, including the AOP frame-
work. The greatest advantage of this would be to ensure
that the key events examined by NAMs translate to an
endocrine‐relevant adverse outcome—that is, there is
sufficient evidence for causal linkages—and ensure that
focus is not just on key events that occur early in the AOP
that could result from compensatory mechanisms. The
relationship between the key event in question and ad-
verse outcome endpoint should be quantitative, high-
lighting the utility and need for quantitative AOPs
(Perkins et al., 2019). The use of bioinformatics, for ex-
ample, to combine predictions with ADME and conduct
in vitro to in vivo extrapolation (IVIVE) will be critical.
Regulatory agencies will need to play a part in the bio-
informatics development process; these approaches
would also have potential to ultimately support a reduc-
tion in the need for range‐finding tests for subsequent in
Integr Environ Assess Manag 2021:1–17 © 2021 The Authorswileyonlinelibrary.com/journal/ieam
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Method Advantages Challenges
▪ Embryonic methods could bridge current in
vitro methods and longer duration in vivo
methods.
▪ Questionable whether ADME in embryos is fully
relevant to in vivo scenarios.
Transcriptomic
approaches
▪ New technologies are enabling rapid testing
using multiple endpoint (toxicity pathway)
approaches (e.g., gene arrays with 100s to
1000s of targets).
▪ Unclear whether transcriptomic changes can be
compensated for and whether they always
represent adverse outcomes. Often assessed
using tissue from in vivo studies (i.e., animal
tests not necessarily avoided).
Abbreviations: ADME, absorption, distribution, metabolism, and excretion; ARE, androgen response element; EATS, estrogenic/androgenic/thyroid/ster-
oidogenesis; ED, endocrine disruption/disruptor; ER, estrogen receptor; IVIVE, in vitro to in vivo extrapolation; MIE, molecular initiating event; MoA, mode of
action; NAM, new approach methodology; OECD, Organization for Economic Cooperation and Development; QSAR, quantitative structure–activity rela-
tionship; TG, test guideline; WoE, weight of evidence.
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vivo studies. The ER pathway model already being ac-
cepted by some regulatory agencies (cf. ECHA/EFSA GD)
could be used as a conceptual model for other types
of receptors. There remains a significant need to expand
on work using mechanistic toxicological information such
as gene expression signatures (e.g., current efforts to
compare ToxCast or “big 'omics” data with apical
outcome data or transcriptomic–apical benchmark dose
modeling).
(d) Improving exposure considerations. This includes further
development of tools that relate applied and intra-
cellular concentrations to whole organism internal
exposures (e.g., through IVIVE) and provision of case
studies to demonstrate their potential utility and
knowledge gaps. This will help to support calibration of
in vitro data against in vivo data and improve knowledge
of concentrations at molecular target sites. Such data
should also include the complexity of both the timing
and duration of exposure that can influence the in vivo
outcome. Exposure activity ratios to place high‐
throughput screening activity in the context of whole
organism exposure could be used as a prioritization tool
(e.g., see Becker et al., 2015) and allow better inter-
pretation across species.
HARNESSING THE OPPORTUNITIES AND
APPLYING 3RS APPROACHES IN PRACTICE
In an ideal world, to conclude that a substance is an EDC,
adverse effects need to be evident with mechanistic data in
the same study (i.e., a proven causal link), with organism
complexity incorporated. We must recognize that not only
is this challenging, but there are also many reasons to
rethink traditional testing paradigms. Therefore, it is abso-
lutely critical that there is a high level of confidence
that the reduction, refinement, or replacement of currently
used in vivo tests provides at least as much, if not more,
useful information for use in a regulatory framework. It must
also be ensured that an increased reliance on NAMs does
not decrease our ability to predict adverse outcomes. This
will be aided by careful consideration of the regulatory
question (or the problem formulation) to determine the
following:
▪ Where in the WoE is more information needed?
▪ How can studies be designed to address that question?
▪ Are more data truly necessary?
In the longer term, adoption of this way of thinking will
support a fundamental paradigm shift that increases the
fitness‐for‐purpose of environmental EDC hazard and risk
assessment, while harnessing the best and most appropriate
science‐driven methodologies. This involves the community
acknowledging that regulatory testing cannot capture ev-
erything as well as assurance that any testing scheme is
environmentally protective. Ideally, there will be a move
away from highly prescriptive or broad‐brush approaches
toward more flexible ways of operating that identify what
is actually needed to answer the scientific and regulatory
questions. At the same time, the limitations to this shift,
including the availability of funding and the capabilities
of the available technologies, must continue to be consid-
ered. The incentive to reach this goal will be increased if it
comes from the top down, as has been the case in other
areas of toxicity testing (e.g., activities resulting from the
USEPA's announcement to prioritize efforts to reduce an-
imal testing, albeit focused on the use of mammals [USEPA,
2019]). In the meantime, the current workshop discussions
have led to the formulation of key recommendations and
identification of activities and efforts needed in the short to
medium term and the medium to long term to support
and inform this paradigm shift, which are outlined below
and in Figure 2.
Short to medium term
Increase efforts and investment into (a) improving NAMs,
(b) addressing pathway and endpoint gaps in both in vivo
and NAM approaches, and (c) IVIVE.
▪ Further develop and standardize in vitro assay batteries
that would comprehensively investigate mechanisms
within a particular endocrine pathway for activity. Greater
incorporation of metabolic competence within in vitro
assay test systems.
▪ Conduct a comprehensive review of the current NAM
landscape to support identification of research needs.
This activity is being initiated by a multistakeholder team
led by NC3Rs and HESI.
▪ Provide access to high‐quality in vivo data, including
increased understanding of the variability and limitations
of animal tests, to both corroborate NAM data and
better understand the underlying adverse effects of
the MoAs.
▪ Provide adequate funding and allocation of resources to
validate and establish which NAMs are best able to re-
duce or replace and improve in vivo testing. This could
include conducting an iterative analysis of the perform-
ance of NAMs (making direct comparisons of the con-
clusions and decisions and hazard or risk assessment
outcomes that would be made based on NAM data vs.
data from traditional test methods).
▪ Build confidence in the ability of embryo assays to predict
adverse effects in laboratory animals by further validating
and defining applicability domains using substances that
have already been tested in in vivo assays.
▪ Develop better kinetic models to estimate internal
exposures and extrapolation from applied doses.
▪ Add more endpoints to existing in vivo tests to maximize
their value, provided that this does not cause additional
suffering or increase the number of test animals used;
examples include ongoing efforts to add thyroid‐relevant
endpoints in fish (a focus within the EURION project
cluster [Holbech et al., 2020] and OECD Project 2.64:
Inclusion of thyroid endpoints in OECD fish TGs).
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▪ Build a high‐quality database of historical data of all types,
to enable reliable modeling tools to be developed further
for the global scientific community.
Review performance criteria.
▪ Conduct more formal regular retrospective analyses
(starting with analysis of historical control data as/when
they become available) to evaluate performance criteria
and increase awareness of the strengths and limitations of
current in vivo methods (e.g., Oris et al., 2012) to (a) in-
crease the value and utility of in vivo test data and (b) to
provide a better benchmark for the NAM.
▪ Use retrospective data to better consider validity criteria
for in vivo TGs, including which criteria are important and
which are less so.
▪ Ensure that there is appropriate ring‐testing during
validation phases, as any new test method must be
reliably repeatable.
▪ Establish better guidance for concentration setting and
interpretation in in vivo tests.
Explore the use of read‐across from mammalian data and
extrapolation between species.
▪ Generation of more information to better enable ex-
trapolation of in vivo information across taxa (for reading
across from mammals to nonmammals and vice versa). This
includes dosimetry considerations and internal exposure
differences, the use of 'omics and/or bioinformatics plat-
forms, and better knowledge of evolutionary genetics and
comparative endocrinology.
▪ Greater training and awareness of models such as
Sequence Alignment to Predict Across Species Suscepti-
bility (SeqAPASS; www.seqapass.epa.gov/seqapass).
▪ Assimilation of case studies comparing regulatory
decisions using mammalian and nonmammalian data.
Are both mammalian and fish or amphibian data always
needed?
Medium to long term
Provide clarity on giving weight to different approaches and
use of existing information.
▪ Move toward a tiered approach globally, which starts with
existing information and prioritization of testing needs.
▪ Organization of knowledge upfront and better use of
the peer‐reviewed and gray literature including incentives
to share unpublished data sets (e.g., all data associated
with publications [Martin et al., 2019]) and/or establishing
a framework to facilitate the sharing of such information.
▪ Development of guidance on assessing overall WoE,
including how to weigh different pieces of information:
this could be a quantitative weighting matrix to use
as a guide. The ERC2 approach developed by Environ-
ment and Climate Change Canada is an example of a
quantitative WoE framework that could be broadened for
use in other jurisdictions and could integrate Bayesian
approaches (Bonnell et al., 2018, 2019). This could in-
clude development of a “threshold of data” that con-
clusively enables waiving of higher‐tier in vivo tests and
addresses the issue of considering data from multiple
NAM sources in place of one in vivo test. It would involve
use of in vitro assay batteries to provide a direct indication
or link to an adverse outcome at the organism or
population level.
▪ Publication of case studies where NAM data have been
used for regulatory decision‐making, including how the
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FIGURE 2 A synthesis of the main workshop outcomes, organized by general topical area as well as projected timeframe
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data were analyzed and synthesized (using a WoE ap-
proach if and where appropriate), to demonstrate how
each data “type” influences decisions.
Improve international harmonization of approaches and
their integration.
▪ Alignment of regulatory approaches (but not necessarily
legislation) based on science both across regions and
countries and sector groups, including harmonization of
the data required to meet the definition of an EDC, in-
terpretation of whether both activity and adversity data
are needed, methods of substance prioritization, and
approaches to managing EDCs (risk‐ vs. hazard‐based).
▪ Where different legal frameworks mandate that different
data types are generated, use problem formulation to
tailor test packages and generate only the necessary and
meaningful data (acknowledging that some regional data
requirements are more flexible than others). In many
cases, companies will be aiming for global marketing and
it should be ensured that packages address international
needs while reducing duplicative or superfluous testing.
Any NAM data generated to meet needs within regional
frameworks could be submitted and viewed by all regu-
latory jurisdictions to help increase confidence in different
approaches.
▪ Ensure greater inclusion of different industry sectors and
regulatory agencies in NAM development, to support
widespread uptake.
SUMMARY AND CONCLUSIONS
This workshop provided a timely opportunity to bring to-
gether experts in the field of nonmammalian vertebrate ED
identification and assessment with varying regional per-
spectives across different regulatory and industry sectors as
well as the academic community. The identification and as-
sessment of endocrine properties of chemicals in fish and
amphibians under current and forthcoming regional require-
ments are driving an increase in the number of animals used
in regulatory testing, particularly in higher‐tier in vivo studies.
It is the ideal time to review the ways in which fish and am-
phibian in vivo studies are performed and interpreted, to
identify where there is scope for improvement, and to assess
how NAMs can contribute in this space. The aim is not only to
reduce the number of animals used but also to simulta-
neously improve the science underlying ED assessment.
The workshop discussions highlighted the notable geo-
graphical differences in approaches and consequences for
substances identified as causing endocrine‐mediated ad-
versity. The needs and requirements for EDC identification
and assessment are highly context dependent, and it is
critical that this is identified and considered upfront via a
problem formulation process, to ensure that only mean-
ingful data are generated and incorporated into decision‐
making. Several 3Rs opportunity areas for in vivo testing
were highlighted, including addressing the need for
improvements to concentration setting and subsequent
data analysis and interpretation; reviewing and updating in
vivo TGs to better understand study performance and the
test validity criteria; ensuring that the tests better address
population relevance; improving the application of WoE
approaches, including better utilization of existing data and
greater consideration of other vertebrate data; adding value
to existing tests through the addition of informative end-
points; and placing more emphasis on better screening
tools to decrease the number of chemicals needing in vivo
testing. Likewise, discussions identified key 3Rs opportunity
areas regarding the use of NAMs, including expanding on
the tools available and increasing coverage of the biological
domains; increasing confidence in their use and data inter-
pretation; improving the application of systems toxicology
approaches; and improving exposure considerations. Ulti-
mately, the goal is to stimulate a fundamental paradigm shift
that increases the fitness‐for‐purpose of environmental EDC
hazard and risk assessment, while harnessing the best and
most appropriate science‐driven methodologies. To this
end, delegates identified several activities and efforts
needed in the short and medium term to support and inform
this paradigm change. Two main HESI and NC3Rs multi-
sector, global follow‐up initiatives aimed at addressing the
short‐term needs are already underway. The first will review
existing in vivo fish and amphibian tests, which are often the
“gold standard” tests to which any new alternative methods
are compared. This work is focused on analysis of historical
control data to evaluate test performance, validity criteria,
and strengths and weaknesses. In addition, it will provide an
objective but critical discussion of the in vivo tests that will
feed into alternative assay development and validation.
The second effort is developing a scientific and technical
summary of existing or under‐development NAMs that are
available to evaluate EATS activity in fish and amphibians.
The aim here is to develop a common set of parameters to
evaluate NAMs and identify gaps where additional method
development is needed. It is acknowledged that some
regulatory agencies may have an immediate need to
move forward in their decision‐making process, while
simultaneously making firm commitments to reduce in vivo
testing (e.g., USEPA, 2019). These decisions should be
based on the best science available, with re‐evaluations of
the state of the science in regular intervals, as necessary.
These are first steps, and it is hoped that the wider
community engages with the recommendations resulting
from the comprehensive workshop discussions and ongoing
follow‐up activity and works together to truly benefit the
3Rs in this field, while at the same time increasing the
robustness, fitness‐for‐purpose, and relevance of regulatory
ED assessments.
ACKNOWLEDGMENT
We are extremely grateful to all 51 workshop delegates
for their participation and valuable input. The workshop was
made possible by financial and in‐kind support from the
NC3Rs and HESI.
Integr Environ Assess Manag 2021:1–17 © 2021 The AuthorsDOI: 10.1002/ieam.4497
3RS FOR INVESTIGATING ED PROPERTIES IN FISH AND AMPHIBIANS—Integr Environ Assess Manag 00, 2021 15
DISCLAIMER
The views and statements expressed in this paper are a
reflection of the workshop on “Investigating Endocrine Dis-
rupting Properties in Fish and Amphibians: Opportunities to
Apply the 3Rs” (held 25 February 2020 in London, UK) as
summarized by the authors. The views or statements ex-
pressed in this publication do not necessarily represent the
views of the organizations to which the authors are affiliated,
and those organizations cannot accept any responsibility for
such views or statements.
DATA AVAILABILITY STATEMENT
All data are presented.
SUPPORTING INFORMATION
A description of the sponsor organizations and the




Michelle R. Embry https://orcid.org/0000-0002-
0376-2743
Thomas H. Hutchinson https://orcid.org/0000-0001-
8823-5442
Scott G. Lynn https://orcid.org/0000-0002-9513-4823




James R. Wheeler https://orcid.org/0000-0002-
9162-5035
REFERENCES
Ankley, G. T., & Jensen, K. M. (2014). A novel framework for interpretation of
data from the fish short‐term reproduction assay (fstra) for the detection
of endocrine‐disrupting chemicals. Environmental Toxicology and
Chemistry, 33(11), 2529–2540.
Becker, R. A., Friedman, K. P., Simon, T. W., Marty, M. S., Patlewicz, G., &
Rowlands, J. C. (2015). An exposure: Activity profiling method for in-
terpreting high‐throughput screening data for estrogenic activity—
Proof of concept. Regulatory Toxicology and Pharmacology, 71(3),
398–408.
Bonnell, M., Inglis, C., Jagla, M., Prindiville, C. J., & Shore, B. (2018). A
computational approach for the ecological prioritization of organic
chemicals in Canada: ERC 2.0. Society of Environmental Toxicology and
Chemistry 39th Annual Meeting, Sacramento, CA, USA.
Bonnell, M., Inglis, C., Jagla, M., Prindiville, C. J., & Shore, B. (2019). De-
velopment of version 2.0 of the ecological risk classification approach for
prioritizing organic chemicals. Society of Environmental Toxicology and
Chemistry Europe 29th Annual Meeting, Helsinki, Finland.
Brooks, A. C., Foudoulakis, M., Schuster, H. S., & Wheeler, J. R. (2019). His-
torical control data for the interpretation of ecotoxicity data: are we
missing a trick?. Ecotoxicology, 28(10), 1198–1209. https://doi.org/10.
1007/s10646‐019‐02128‐9
Burden, N., Sewell, F., & Chapman, K. (2015). Testing chemical safety: What is
needed to ensure the widespread application of non‐animal approaches?
PLoS Biology, 13(5), e1002156.
European Chemicals Agency/European Food Safety Authority (ECHA/EFSA).
(2018). Guidance for the identification of endocrine disruptors in the
context of regulations (EU) no 528/2012 and (EC) no 1107/2009. EFSA
Journal, 16(6), e05311.
European Food Safety Authority (EFSA). (2005). Opinion of the scientific
panel on animal health and welfare (AHAW) on a request from the
commission related to the aspects of the biology and welfare of animals
used for experimental and other scientific purposes. EFSA Journal, 3
(12), 292.
European Food Safety Authority (EFSA). (2017). Guidance on the use of the
weight of evidence approach in scientific assessments. EFSA Journal, 15
(8), e04971.
European Commission. (2010). Directive 2010/63/EU of the European Par-
liament and of the Council of 22 September 2010 on the protection of
animals used for scientific purposes. Official Journal of the European
Union, 276, 34–79.
Holbech, H., Matthiessen, P., Hansen, M., Schüürmann, G., Knapen, D.,
Reuver, M., Flamant, F., Sachs, L., Kloas, W., Hilscherova, K., Leonard, M.,
Arning, J., Strauss, V., Iguchi, T., & Baumann, L. (2020). Ergo: Breaking
down the wall between human health and environmental testing of
endocrine disrupters. International Journal of Molecular Sciences,
21(8), 2954.
Hutchinson, T. H., Bögi, C., Winter, M. J., & Owens, J. W. (2009). Benefits of
the maximum tolerated dose (MTD) and maximum tolerated concen-
tration (MTC) concept in aquatic toxicology. Aquat Toxicol, 91(3), 197–
202. https://doi.org/10.1016/j.aquatox.2008.11.009
Japan Ministry of the Environment. (2010). Further actions to endocrine dis-
rupting effects of chemical substances: EXTEND 2010. Available at:
https://www.env.go.jp/en/chemi/ed/extend2010_full.pdf. Accessed 5
February 2021.
Judson, R. S., Magpantay, F. M., Chickarmane, V., Haskell, C., Tania, N.,
Taylor, J., Xia, M., Huang, R., Rotroff, D. M., Filer, D. L., Houck, K. A.,
Martin, M. T., Sipes, N., Richard, A. M., Mansouri, K., Setzer, R. W.,
Knudsen, T. B., Crofton, K. M., & Thomas, R. S. (2015). Integrated model
of chemical perturbations of a biological pathway using 18 in vitro high‐
throughput screening assays for the estrogen receptor. Toxicological
Sciences, 148(1), 137–154.
Karmaus, A. L., Toole, C. M., Filer, D. L., Lewis, K. C., & Martin, M. T. (2016).
High‐throughput screening of chemical effects on steroidogenesis using
h295r human adrenocortical carcinoma cells. Toxicological Sciences,
150(2), 323–332.
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G.
(2010). Improving bioscience research reporting: The ARRIVE guidelines
for reporting animal research. PLoS Biol, 8(6), e1000412. https://doi.org/
10.1371/journal.pbio.1000412
Kleinstreuer, N. C., Ceger, P., Watt, E. D., Martin, M., Houck, K., Browne, P.,
Thomas, R. S., Casey, W. M., Dix, D. J., Allen, D., Sakamuru, S., Xia, M.,
Huang, R., & Judson, R. (2017). Development and validation of a com-
putational model for androgen receptor activity. Chemical Research in
Toxicology, 30(4), 946–964.
Kleinstreuer, N. C., Ceger, P. C., Allen, D. G., Strickland, J., Chang, X.,
Hamm, J. T., & Casey, W. M. (2016). A curated database of rodent ute-
rotrophic bioactivity. Environmental Health Perspectives, 124(5),
556–562.
Lagadic, L., Bender, K., Burden, N., Salinas, E. R., & Weltje, L. (2019). Rec-
ommendations for reducing the use of fish and amphibians in endocrine‐
disruption testing of biocides and plant protection products in Europe.
Integrated Environmental Assessment and Management, 15(4), 659–662.
Lagadic, L., Wheeler, J. R., & Weltje, L. (2020). (Mis)use of the adverse out-
come pathway concept for assessing endocrine disruption in nontarget
organisms. Integrated Environmental Assessment and Management,
16(4), 525–528.
LaLone, C. A., Villeneuve, D. L., Lyons, D., Helgen, H. W., Robinson, S. L.,
Swintek, J. A., Saari, T. W., & Ankley, G. T. (2016). Editor's highlight:
Sequence alignment to predict across species susceptibility (seqapass):
A web‐based tool for addressing the challenges of cross‐species
extrapolation of chemical toxicity. Toxicological Sciences, 153(2),
228–245.
Martin, O. V., Adams, J., Beasley, A., Belanger, S., Breton, R. L., Brock, T. C.
M., Buonsante, V. A., Galay Burgos, M., Green, J., Guiney, P. D., Hall, T.,
Integr Environ Assess Manag 2021:1–17 © 2021 The Authorswileyonlinelibrary.com/journal/ieam
16 Integr Environ Assess Manag 00, 2021—BURDEN ET AL.
Hanson, M., Harris, M. J., Henry, T. R., Huggett, D., Junghans, M.,
Laskowski, R., Maack, G., Moermond, C., … Ågerstrand, M. (2019).
Improving environmental risk assessments of chemicals: Steps towards
evidence‐based ecotoxicology. Environment International, 128, 210–217.
Marty, S. M., Borgert, C., Coady, K., Green, R., Levine, S. L., Mihaich, E.,
Ortego, L., Wheeler, J. R., Yi, K. D., & Zorrilla, L. M. (2018). Distinguishing
between endocrine disruption and non‐specific effects on endocrine
systems. Regulatory Toxicology and Pharmacology, 99, 142–158. https://
doi.org/10.1016/j.yrtph.2018.09.002
McArdle, M. E., Freeman, E. L., Staveley, J. P., Ortego, L. S., Coady, K. K.,
Weltje, L., Weyers, A., Wheeler, J. R., & Bone, A. J. (2020). Critical review
of read‐across potential in testing for endocrine‐related effects in verte-
brate ecological receptors. Environmental Toxicology and Chemistry, 39
(4), 739–753.
Moermond, C. T. A., Kase, R., Korkaric, M., & Ågerstrand, M. (2016). CRED:
Criteria for reporting and evaluating ecotoxicity data. Environmental
Toxicology and Chemistry, 35(5), 1297–1309.
Organization for Economic Cooperation and Development (OECD). (2012).
Guidance document on standardized test guidelines for evaluating
chemicals for endocrine disruption. OECD series on testing and assess-
ment no. 150. p. 524.
Organization for Economic Cooperation and Development (OECD). (2018a).
Case study on the use of integrated approaches for testing and assess-
ment (IATA) for estrogenicity of the substituted phenols. OECD series on
testing and assessment no. 290. Env/jm/mono(2018)26, Paris.
Organization for Economic Cooperation and Development (OECD). (2018b).
Revised guidance document 150 on standardised test guidelines for
evaluating chemicals for endocrine disruption, OECD series on testing
and assessment, no. 150, OECD Publishing, Paris. https://doi.org/10.
1787/9789264304741‐en
Oris, J. T., Belanger, S. E., & Bailer, A. J. (2012). Baseline characteristics and
statistical implications for the OECD 210 fish early‐life stage chronic
toxicity test. Environmental Toxicology and Chemistry, 31(2), 370–376.
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M.,
Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner,
P. A., Holgate, S., Howells, D. W., Karp, N., Lidster, K., MacCallum, C. J.,
Macleod, M. R., Petersen, O., … Rawle, F. (2019). The ARRIVE guidelines
2019: Updated guidelines for reporting animal research. bioRxiv. 703181.
Perkins, E. J., Ashauer, R., Burgoon, L., Conolly, R., Landesmann, B., Mackay,
C., Murphy, C. A., Pollesch, N., Wheeler, J. R., Zupanic, A., & Scholz, S.
(2019). Building and applying quantitative adverse outcome pathway
models for chemical hazard and risk assessment. Environ Toxicol Chem,
38, 1850–1865. https://doi.org/10.1002/etc.4505
Russell, W. M. S., & Burch, R. L. (1959). The principles of humane ex-
perimental technique. Methuen.
Scholz, S., Renner, P., Belanger, S. E., Busquet, F., Davi, R., Demeneix, B. A.,
Denny, J. S., Léonard, M., McMaster, M. E., Villeneuve, D. L., & Embry,
M. R. (2013). Alternatives to in vivo tests to detect endocrine disrupting
chemicals (EDCS) in fish and amphibians—screening for estrogen, an-
drogen and thyroid hormone disruption. Critical Reviews in Toxicology,
43(1), 45–72.
Solomon, K. R., Wilks, M. F., Bachman, A., Boobis, A., Moretto, A., Pastoor,
T. P., Phillips, R., & Embry, M. R. (2016). Problem formulation for risk
assessment of combined exposures to chemicals and other stressors in
humans. Critical Reviews in Toxicology, 46(10), 835–844.
Suter, G., Nichols, J., Lavoie, E., & Cormier, S. (2020). Systematic review and
weight of evidence are integral to ecological and human health assess-
ments: They need an integrated framework. Integrated Environmental
Assessment and Management, 16(5), 718–728.
US Environmental Protection Agency (USEPA). (2009). EPA's approach for
considering Other Scientifically Relevant Information (OSRI) under the
Endocrine Disruptor Screening Program (No. EPA‐HQ‐OPPT‐2007‐1080‐
0059). US Environmental Protection Agency, Washington, DC. https://
www.regulations.gov/document/EPA-HQ-OPPT-2007-1080-0059
US Environmental Protection Agency (USEPA). (2011). Endocrine Disruptor
Screening Program (EDSP), weight of evidence: Evaluating results of
EDSP tier 1 screening to identify the need for tier 2 testing. https://www.
regulations.gov/document/EPA-HQ-OPPT-2010-0877-0021
US Environmental Protection Agency (USEPA). (2015). Use of high throughput
assays and computational tools in the endocrine disruptor screening
program. https://www.regulations.gov/document/EPA-HQ-OPPT-2015-
0305-0001












US Environmental Protection Agency (USEPA). (2017). Continuing
development of alternative high‐throughput screens to determine
endocrine disruption, focusing on androgen receptor, steroidogenesis,
and thyroid pathways. https://www.regulations.gov/docket/EPA-HQ-OPP-
2017-0214
US Environmental Protection Agency (USEPA). (2019, September 10).






US Environmental Protection Agency (USEPA). (2020). Endocrine disruptor





Webster, F., Gagné, M., Patlewicz, G., Pradeep, P., Trefiak, N., Judson, R. S.,
& Barton‐Maclaren, T. S. (2019). Predicting estrogen receptor activation
by a group of substituted phenols: An integrated approach to testing and
assessment case study. Regulatory Toxicology and Pharmacology, 106,
278–291.
Wheeler, J. R., Panter, G. H., Weltje, L., & Thorpe, K. L. (2013). Test con-
centration setting for fish in vivo endocrine screening assays. Chemo-
sphere, 92(9), 1067–1076.
Wheeler, J. R., Valverde‐Garcia, P., & Crane, M. (2019). Control
performance of fish short term reproduction assays with fathead minnow
(pimephales promelas). Regulatory Toxicology and Pharmacology, 108,
104424.
World Health Organization/International Programme on Chemical Safety
(WHO/IPCS). (2002). The International Programme on Chemical Safety
(IPCS): Global assessment of the state‐of‐the‐science of endocrine
disruptors. World Health Organization.
Integr Environ Assess Manag 2021:1–17 © 2021 The AuthorsDOI: 10.1002/ieam.4497
3RS FOR INVESTIGATING ED PROPERTIES IN FISH AND AMPHIBIANS—Integr Environ Assess Manag 00, 2021 17
